



Review Article

## The Increasing Burden of Uncontrolled Hypertension in Nigeria: The Role of Lifestyle Modification Practices as an Effective Strategy to Reverse the Trend

Iyalomhe GBS<sup>1</sup>, Iyalomhe SI<sup>2</sup>

<sup>1</sup>Associate Professor & Head, Department of Pharmacology and Therapeutics, College of Medicine, Ambrose Alli University, Ekpoma, Nigeria

<sup>2</sup>Head, Department of Public Health and Primary Health Care, Central Hospital, Auchi, Nigeria

Corresponding Author: Iyalomhe GBS

Received: 17/11/2014

Revised: 10/12/2014

Accepted: 12/12/2014

### ABSTRACT

**Background:** Globally, uncontrolled hypertension is a serious prevalent risk factor for cardiovascular and renal diseases. The current approach to the control of hypertension and its complications includes drug treatment of hypertensive patients and implementation of adequate lifestyle modifications (LMs) which are beneficial for non-hypertensive and hypertensive individuals. Practices of LMs are abysmally low in Nigeria.

**Aim:** This review aims to provide healthcare professionals with useful clinical information to guide their patient care promote the understanding of LMs and motivate hypertensive patients and the public to adopt and maintain multiple LMs.

**Methodology:** Manual literature and computer programmes (Cochrane Library, EMBASE, OVID, Pub Med, HINARI, Goggle Scholar etc) were searched for relevant information.

**Results/Discussion:** The search showed that LM practices such as regular physical activity/exercises, weight loss by the overweight or obese, reduced salt and increase potassium (K<sup>+</sup>) intake, adoption of the Dietary Approaches to Stop Hypertension (DASH) diet (that emphasizes consumption of fruits, vegetables, low-fat dairy products, reduced saturated fat and cholesterol), moderation in alcohol intake and cessation of smoking, have significant beneficial effects on blood pressure (BP). High religiosity or spirituality promotes cardiovascular health possibly by its preventive or prohibitive influence on lifestyle risk factors such as smoking and excessive alcohol drinking.

**Conclusion:** The current challenge to healthcare providers and the public is evolvment and implementation of effective clinical and public health strategies that lead to sustained LM practices. There is urgent need to intensify LM education and counseling to both hypertensive patients and the public, particularly in Nigeria.

**Key words:** Uncontrolled hypertension, Lifestyle modification, Strategy for controlling hypertension, Nigeria.

### INTRODUCTION

Cardiovascular diseases (CVDs), mostly heart disease and stroke, account for

a third of deaths worldwide with about 80% of these deaths happening in low and middle income countries.<sup>1</sup> The biggest risk factor in

CVD is hypertension, as it is directly responsible for 62% of strokes and 49% of heart disease. [1,2] The International Forum for Hypertension Control and Prevention in Africa suggested that strategies that modify the risk factor for hypertension, such as promoting healthy diets, weight reduction, reducing salt intake, smoking cessation and moderation in alcohol intake and engaging in physical exercises, could lower the prevalence of high blood pressure and subsequently reduce the burden of CVD. [3] This combination of strategies is also recommended in the guidelines on hypertension by the various Hypertension Writing Groups such as the World Health Organization (WHO)/International Society of Hypertension (ISH). [4] European Society of Hypertension (ESH)/European Society of Cardiology (ESC) [5] and the US 8th Joint National Committee for the Prevention, Detection, Evaluation and Treatment of High Blood Pressure. [6] Aside from other risk factors such as tobacco use, undernutrition, unsafe water and unsafe sex, hypertension is reported to rank highest as a preventable cause of death in both developed as well as in developing countries such as Nigeria where hypertension and urbanization have been close companions. [1,5,7,8]

It has long been recognized that drug treatment alone is an incomplete solution to the epidemic of high BP. [1-69-11] It is known that the risk of BP-related cardiovascular and renal disease increases progressively throughout the range of BP, including ranges of BP previously considered normal but now called prehypertension. Although the number of patients with hypertension and prehypertension continues to rise and affects a large portion of the population, recognition and adequate treatment are grossly inadequate. [12]

The cost of drug treatment of hypertension represents a significant amount

of healthcare resources use and the total annual medical expenditure attributed to hypertension including comorbidities are estimated to range from USD 108-110 billion. [13,14] The adverse effects such as dizziness, headache, fatigue, chest discomfort, cough, sexual dysfunction, caused by some antihypertensive drugs, may prompt some patients to discontinue therapy, predisposing them to the danger of cardiovascular events. But LMs are cheap and have virtually no side effect. [15-17]

In view of the above considerations, national and international policy-making bodies recommend LM practices as a means to prevent and treat hypertension and thereby prevent cardiovascular and renal disease in the whole population. [1-8,10,18]

## **THE BURDEN OF UNCONTROLLED HYPERTENSION IN NIGERIA**

In Nigeria, hypertension is a serious major public health and clinical problem that causes disability and death among the adult population as well as playing an important role in the causation of heart failure, heart attack, stroke, renal failure, and arteriosclerosis in the population. [19,20] Indeed, it has been reported that the incidence of hypertension is rising in Nigeria. [21-26] A nation-wide survey [27] in 1992 showed that 11.2% of adults were hypertensive but recent studies done in different parts of the country have shown prevalence rates that ranged from 28.8% to 36.6% [22,24-26] This increasing burden of hypertension is stretching medical facilities in Nigeria and this is shown by increase rate of in-patient hospital admissions for strokes and heart disease. [28-30] Therefore, there is a need for population-wide strategies to prevent hypertension in Nigeria before it becomes an unmanageable epidemic. [31]

Recent surveys in Nigeria reveal continuing deficiencies in the knowledge, perception, prevention and control of

hypertension. In most cases, failure to achieve BP control was attributed to the poverty of patients' knowledge and lack of or inadequate practice of LMs. [21,28,29,32,33] The result is that excess morbidity and premature mortality from severe hypertension have remained high among Nigerian patients. [34,35] Worse still, the coexistence of hypertension and diabetes in this group dramatically and synergistically increases the risk of microvascular and macrovascular complications, a worrisome condition associated with widespread disability, excess mortality, reduced capacity for work and disruption of social/family life among the indigenous people. [36-38]

Thus hypertension has become a big burden in Nigeria, a country experiencing the epidemiological transition from communicable to non-communicable diseases, a phenomenon referred to as a *double burden of disease*. Rural-to-urban migration coupled with acculturation and modernization has become the trend that is strongly linked with changes in individual and societal lifestyles such as an increase in tobacco use, excessive alcohol consumption, reduced physical activity and adoption of western diets that are high in salt, refined sugar and unhealthy fats and oils. [32,35]

## **THE ROLE OF LIFESTYLE MODIFICATIONS (LMs) AS AN EFFECTIVE STRATEGY TO REDUCE HYPERTENSION**

LMs, previously referred to as non-pharmacological therapy, have important roles in hypertensive and non-hypertensive individuals. In hypertensive individuals, LMs can serve as initial treatment before the commencement of antihypertensive therapy and as an adjunct to medications in persons already on drug therapy. [11,12] In hypertensive individuals with medication-controlled BP, these therapies can facilitate drug step-down and drug withdrawal in

highly motivated individuals who are consistent with LM practices. [35] In non-hypertensives, LMs have the potential to prevent hypertension, and more broadly to reduce BP and its complications in whole (including prehypertensive) population. Indeed, even an apparently small reduction in BP, if applied to an entire population, could have an enormous beneficial effect on cardiovascular events. For instance, a 3 mmHg reduction in systolic BP should lead to an 80% reduction in stroke mortality and a 5% reduction in mortality from coronary heart disease. [9,12]

It is remarkable that hypertension, the key driver of cardiovascular complications, is mainly associated with environmental and lifestyle factors rather than with genetics and has a stronger association and causal link with the following modifiable (reversible) risk factors that can reduce BP if properly utilized. [9,12,35]

### **Regular physical activity/exercise**

Adequate physical activity including regular aerobic (isotonic) exercises such as brisk walking, dancing, swimming, jogging 30-45 minutes 3-4 days a week, has been shown to have health promoting benefits and has a direct, independent role in reducing BP. Hence, even in elderly people, tolerance exercise is advised. [35,39-41]

Hitherto, it was thought that a high level of physical activity could in part explain the low level of chronic disease found in most of Africa. However, the amount of physical activity has decreased as a result of a high rate of urbanization. Adequate physical activity is more prevalent in rural than urban areas of Nigeria, which partly explains the high prevalence of obesity in urban areas. [15,21,35-38] Government and stakeholders should motivate and mobilize the citizenry to engage in useful physical activities.

## Maintaining a healthy body weight

Observational studies and virtually every clinical trial, that have examined the effect of weight loss on BP, have documented that weight reduction in the overweight or obese lowers BP. [42-45] Interestingly, reductions in BP occur before (and without) attainment of desirable body weight. Since the mean weight of populations is not stable but has increased in recent years world-wide, lifestyle intervention trials have uniformly achieved short term weight loss (that is, the efficacy of weight control interventions is lost with time). [5] However, in several instances, substantial weight loss has been sustained for over 3 years. [43,44,46]

## Reducing dietary table salt (sodium (Na<sup>+</sup>) chloride) intake

A high intake of salt has adverse effect on BP. Evidence includes results from animal [47] and epidemiologic [48,49] studies as well as clinical trials. [50-52] These studies demonstrate that hypertension can be induced in both salt-sensitive animals and humans by high dietary salt load. Salt (Na<sup>+</sup>) sensitivity is the hallmark of hypertension in the majority of blacks, the obese as well as the elderly and they respond very well to Na<sup>+</sup> restriction and to diuretics/natriuretic agents. [17,34,36,52-56]

Essential hypertension is seen primarily in societies with average Na<sup>+</sup> intake above 100 mmol/day (2.3g Na<sup>+</sup>). [50,57] These observations suggest that the development of hypertension requires a threshold level of Na<sup>+</sup> intake and this effect appears to be independent of other risk factors for hypertension eg obesity. Reducing Na<sup>+</sup> intake to 100 mmol/day has been reported to lower the mean BP in normotensive adults by approximately 2/1 mmHg and in hypertensive adults by 5/3 mmHg. [58] It has therefore been suggested that the inexorable and deleterious natural history of BP rising with aging in societies

consuming large amounts of salt, such as Nigeria, [33] could be aborted in the very beginning by a low-salt diet. [59] Above data have reinforced current guidelines to limit salt intake to 6g per day, the equivalent of 100 mmol of Na<sup>+</sup> (2400 mg) per day. Results from the DASH Na<sup>+</sup> feeding study [52] have documented that an even lower intake of Na<sup>+</sup>, approximately 60 mmol/day, further reduces BP in a broad population of non-hypertensive and hypertensive individuals.

Low salt intake not only reduces BP and its related CVD risk, but also has additional benefits such as direct effect on reducing stroke, left ventricular hypertrophy, aortic stiffness as well as chronic kidney disease and proteinuria. [9,35,51] Salt reduction in the diet (low salt in cooking and no additional salt at table) at the population-wide level as a means of reducing the burden of hypertension in Nigeria could be one of the *best buy strategies* due to its attractive low cost of implementation. [32,35,60,61]

## Increasing potassium (K<sup>+</sup>) intake

In various human populations (and animals too), high BP is correlated more closely with low K<sup>+</sup> intake than with high Na<sup>+</sup> intake and hypertensive patients have been found to have lower plasma and total body K<sup>+</sup> as well as lower urine K<sup>+</sup> excretion levels. [53,54,56] Potassium supplementation or high K<sup>+</sup> diet including fresh fruits like bananas, oranges, apples and vegetables (the preferred strategy to increase K<sup>+</sup> intake because this is accompanied by a variety of other nutrients), has been demonstrated to lower BP (more in hypertensives than normotensives), potentiate the effects of diuretics and lessen renal K<sup>+</sup> wasting. [62] However, a subsequent report of a systematic review of available meta-analyses and randomized controlled trials found no statistically significant effect of K<sup>+</sup> supplementation on BP excluding one trial

in an African population with very high baseline BP that resulted in small overall reductions in BP. [63]

**Other dietary factors that might influence BP: Calcium ( $\text{Ca}^{2+}$ ), Magnesium ( $\text{Mg}^{2+}$ ), Zinc ( $\text{Zn}^{2+}$ ), high protein intake, DASH-diet**

Hypertension is more common in the presence of hypercalcaemia and there is direct positive relationship between total serum  $\text{Ca}^{2+}$  and BP. [64]  $\text{Ca}^{2+}$  supplements may lower the blood pressure in those who have lower serum  $\text{Ca}^{2+}$  [65] and high parathyroid hormone level but with the potential risk of causing kidney stones. [66] Increase in  $\text{Na}^+$  may increase BP, whereas the reverse is for  $\text{K}^+$  and  $\text{Mg}^{2+}$ , hence dietary measures to reduce BP have been reported to be more effective when intake of several minerals is affected simultaneously. [67] This is because the cations ( $\text{Na}^+$ ,  $\text{K}^+$ ,  $\text{Mg}^{2+}$ ,  $\text{Ca}^{2+}$ ) functionally act in concert. [68,69]  $\text{Mg}^{2+}$  deficiency is associated with significant hypertension [70] and oral  $\text{Mg}^{2+}$  supplementation has been reported to prevent and lower BP. [71] Reducing  $\text{Na}^+$  intake together with increasing  $\text{Ca}^+$  and  $\text{Mg}^{2+}$  intake are important in the prevention and treatment of hypertension. [67] The US National Health and Examination Nutrition Survey (NHANES II 1976-1980) found an inverse relationship between serum  $\text{Zn}^{2+}$  level and BP. [72]

Epidemiological studies strongly support the hypothesis that increased protein intake can lower BP. [73] The most effective diet, now termed the DASH diet, [9] emphasizes fruits, vegetables, and low-fat dietary products; includes whole grains, poultry, fish and nuts; and is reduced in fat, red meat, sweets, and sugar-containing beverages. The diet is rich in  $\text{K}^+$ ,  $\text{Mg}^{2+}$ , and  $\text{Ca}^{2+}$ . Among non-hypertensive individuals, this diet reduced systolic and diastolic BP by 3.5 and 2.1 mmHg, respectively. In hypertensives, corresponding BP reductions

were striking, i.e., 11.4 and 5.5 mmHg. Similar to the meta-analysis of  $\text{K}^+$ , the DASH diet reduced BP to a greater extent in blacks than non-blacks. [74]

**Moderation in alcohol intake (among drinkers)**

Consumption of alcohol is increasingly becoming more frequent in Africa including Nigeria. [7,35] The effects of heavy [75] and even moderate [76,77] drinking leading to increased BP has been reported in Nigeria and elsewhere, respectively. Trials have also reported that reductions in alcohol intake can lower BP in normotensive and hypertensive men who are heavy drinkers. [78,79] Evidence supports a recommendation to limit alcohol intake to  $\leq 1$  drink per day for women and  $\leq 2$  drinks per day for men, in the absence of binge drinking. One drink is defined as 12 oz of regular beer, 5 oz of wine (12% alcohol), and 1.5 oz of 80-proof spirit, all equivalent to about 15g alcohol. [80] The plausible beneficial effects of this level of alcohol consumption include reduction in platelet aggregation and thrombotic markers such as fibrinogen, increases in HDL cholesterol (about 80%) [81] and anti-inflammatory effects such as lowering C- reactive protein levels. [82] However, amounts in or near this level have been associated with an increased risk for hypertension, [76,77] although it is said that this may be due to heavy drinkers who under report their intake. [77,83] Again, this beneficial effects of moderate alcohol drinking are not evident in South Asians, [84] Indian men [85] and American blacks. [86]

Thus, according to Naimi and colleagues, [87] alcohol is not a good candidate as a population-based hypertension prevention strategy especially when one considers the special concerns about addiction, cost of alcoholism on family life, drunk driving, treatment of liver disease, atrial fibrillation, stroke, cardiomyopathy, cancer and dementia.

Hence the current advice of the American Heart Association in relation to alcohol and prevention of hypertension and other cardiovascular diseases is “If you drink alcohol, do so in moderation. If you don’t drink, don’t start.”<sup>[80]</sup> Interventions to limit alcohol use should be introduced in a multi-sectoral manner and adapted to the local situation. Such interventions, like the ones utilized for reducing tobacco use, can also be applicable eg increasing taxes on alcohol, and banning alcohol advertising especially to young people.<sup>[88]</sup>

### **Cessation of cigarette smoking**

Among its many negative effects, smoking increases BP and the harms associated with hypertension by damaging blood vessels and hardening arteries (atherosclerosis), which can lead to impaired organ function and blood clots.<sup>[89,90]</sup> Moreover, as a group, smokers tend to have more behavioural risk factors than do non-smokers, including poorer diet, less frequent exercises, and higher alcohol consumption, which also put them at greater risk for developing more severe forms of hypertension.<sup>[91]</sup> Smoking cessation is known to reduce the overall risk of cardiovascular diseases.<sup>[92]</sup> In order to reduce smoking at the population level, it is important to implement multi-sectoral interventions like increasing taxes on tobacco products, banning of tobacco advertisements and banning smoking in public places.<sup>[88]</sup>

### **High religiosity or spirituality**

The concept that religious behaviour, religiosity or spirituality, was associated with longevity was observed in the 1990s, when mortality was found to be lower among frequent church-goers than among non-attenders.<sup>[93]</sup> One proposed mechanism for improving mortality among healthy, religious individuals is reduced cardiovascular risk, possibly related to lifestyle or other cardioprotective effects of

religious behaviour such as its prohibitive influence on smoking or alcoholism.<sup>[94,95]</sup>

The above is true of many religious groups in Nigeria and it should be encouraged because it is an effective strategy for controlling these deleterious risk factors for hypertension.<sup>[24,28]</sup>

## **CONCLUSION**

Although each LM practice has a modest effect, the combined (comprehensive LM) effects, particularly the ones involving DASH-diet, exercise and weight loss, can be substantial. From a public health perspective, even a small reduction in BP should have a significant beneficial effect on the occurrence in prehypertension/hypertension and their complications. Given the current high prevalence of BP-related diseases and the established salutary effects of LMs on BP, public health policies should be focussed on reducing the risk factors of hypertension. This can be done by developing and implementing hypertension control programmes just like the concerted efforts of the Federal, State and the Local Governments that attended the eradication of guinea worm, poliomyelitis and the recent ebola virus disease infections in the country. Government at all levels should put in place effective monitoring and surveillance programmes in order to track progress in reducing the prevalence of hypertension and its control.

There should be a strong focus on development and improvement in the health service delivery system to address the control of hypertension and its complications. This can be done through community based screening programmes and strengthening primary health care system to manage simple cases of hypertension but also establishing a strong referral link to General Hospitals and tertiary health facilities to ensure continuity of care. Antihypertensives should be made

free or highly subsidized and available. There should be continued training and retraining of medical and allied health staff as well as developing and implementing National standard guidelines for treatment and management of hypertension to ensure consistent quality care of hypertensive patients. There is urgent need to intensify LM education and counseling to both hypertensive patients and the public, particularly in Nigeria.

## REFERENCES

1. WHO Global Health Observatory (2013). Raised blood pressure: situations and trends [online]. Gxmed August 6, 2014] Available at URL: <http://www.who.int/gho/ncd/riskfactors/bloodpressureprevalencetext/en>.
2. WHO. Preventing chronic disease, a vital investment. 2005; Geneva.
3. Lemogun D, Seedat YK, Mabadeje AF, Mendis S, Bovet P, Onwubere B et al. Recommendations for prevention, diagnosis and management of hypertension and cardiovascular risk factors in Sub-Saharan Africa, *J Hypertens*. 2003; 21: 1993-2000.
4. Witworth JA et al for the WHO/ISH Writing Group. WHO/ISH statement on management of hypertension. *J Hypertens*. 2003; 21(ii): 1983-1992.
5. Mancia G, Fagard R, Narkiewicz et al. Practice guidelines for the management of arterial hypertensive of the ESH/ESC. *J Hypertens*. 2013; 31:1925-1938.
6. James PA, Oparil S, Carter BL et al for the panel members appointed to the US 8<sup>th</sup> JNC for the Prevention. Detection, Evaluation and Treatment of High Blood Pressure. 2014 evidence-based guidelines for the management of high blood pressure in adults. *JAMA*. 2014; 311 (5):507-520.
7. Ezzati M, et al. Selected major risk factors and global and regional burden of disease. *Lancet*. 2002; 360(9343):1347-1360.
8. WHO. Health statistics information systems. The Global Burden of Disease and injury country estimates (internet). 2011; Available from: [http://www.who.int/healthinfo/global\\_burden\\_disease/estimates\\_country/en/index.htm](http://www.who.int/healthinfo/global_burden_disease/estimates_country/en/index.htm) [accessed 11/08/2014].
9. Appel LJ. Lifestyle modification as a means to prevent and treat high blood pressure. *J Am Soc Nephrol*. 2003; 14: 599-5102.
10. Glynn LG, Murphy AW, Schroeder K, Fahey TC. Interventions used to improve control of blood pressure in patients with hypertension, *Cochrane Data Base of System Rev, Issue 3 Art No CDOO5182*. 2013; DOI: 0.1002/114651858. CDOO5182.pub4.
11. Iyalomhe GBS. A review of the current trends in the treatment of hypertension. *J Appl Bas Sc* 2005; 3(1&2):5-9.
12. Li J, Zheng H, Du H, Tian X, Jiang y, Zang S et al. The multiple lifestyle modifications for patients with prehypertension and hypertension: a systematic review protocol. *BMJ Open*. 2014; 4: e004920. DOI: 10.1136/bmjopen-2014-004920.
13. Balu S, Thomas J III. Incremental expenditure of treating hypertension in the United States. *Am J Hypertens*. 2006; 19:810-816.
14. Hodgson TA, Cai L. Medical care expenditures for hypertension, its complications and its comorbidities. *Med Care*. 2001; 39:599-615.
15. Iyalomhe GBS, Omogbai EKI, Isah AO, Iyalomhe OOB, Dada FL, Iyalomhe SI, Efficacy of initiating therapy with amlodipine and hydrochlorothiazide or their combination in hypertensive Nigerians. *Clin Exper Hypertens Early online* 1-8 2013; DOI: 10.3109/10641963.776570.
16. Iyalomhe GBS, Compliance to antihypertensive therapy. *Nig Clin Rev J*. 2007; 63: 12-16.
17. Iyalomhe GBS, Current trends in diuretic therapy of hypertension. *Nig Clin Rev J*. 2007; 61: 25 – 29.

18. Federal Ministry of Health, Nigeria. Standard Treatment Guidelines. Abuja, Federal Ministry of Health, Nigeria, 2008.
19. Ayodele OE, Alebiosu CO, Salako BL, Awoden OG, Adigun A. Target organ damage and associated clinical conditions among Nigerians with treated hypertension. *Cardiovasc J South Afr.* 2005; 16: 89-93.
20. Arodiwe EB, Ike SO, Nweokediuto SC. Case fatality among hypertension-related admissions in Enugu, Nigeria. *Nig J Clin Pract.* 2009; 12:153-156.
21. Akinkugbe OO. Current epidemiology of hypertension in Nigeria. *Arch. Ibadan Med.* 2003; 1:3-5.
22. Adedoyin RA, et al. Prevalence and pattern of hypertension in a semi-urban community in Nigeria. *Eur J Cardiovasc Prev Rehab.* 2008; 15(6):638-687.
23. Ike SO. Prevalence of hypertension and its complications among medical admissions at the University of Nigeria Teaching Hospital, Enugu (study 2). *Nig J Med.* 2009; 18(1):68-72.
24. Isezuo SA, Sabir AA, Ohwovoriolae AE, Fasanmade OA. Prevalence, associated factors and relationship between prehypertension and hypertension: a study of two ethnic African populations in Northern Nigeria. *J Hum Hypertens.* 2010; Jun 17. [Epub ahead of print].
25. Ulasi, II, Ijoma CK, Onodugo OD. A community-based study of hypertension and cardio-metabolic syndrome in semi-urban and rural communities in Nigeria. *BMC Health Services Res.* 2010; 10:71-78.
26. Ekwunife OL, Udeogaranya PO, Nwatu IL. Prevalence, awareness, treatment and control of hypertension in a Nigerian population. *Health.* 2013; 2 (7):731-735.
27. Akinkugbe OO, et al. Non-communicable Diseases in Nigeria-Final report of a National Survey .Lagos: Federal Ministry of Health, Abuja. 1997.
28. Iloh GUP, Ofoedu JN, Njoku PU, Amadi AN, Godswill-UKo EU. Medication adherence and blood pressure control amongst adults with primary hypertension attending a tertiary primary care clinic in Eastern Nigeria. *Afr J Prim Health Care Fam Med.* 2013; 5:446-501.
29. Katibi IA, Olarinoye JK, Kuranga SA. Knowledge and practice of hypertensive patients as seen in a tertiary hospital in the middle belt of Nigeria. *Nig J Clin Pract.* 2010; 13:159-162.
30. Ekwunife OL, Aguwa CN, Adibe MO, Barikpoar E, Onwuka C. Health state utilities of a population of Nigerian hypertensive patients. *BMC Res Notes.* 2011; 4:528. DOI: 10.1186/1756-05000-4-528.
31. Kuller LH. Epidemic hypertension in Sub-Saharan Africa. *Hypertens.* 2007; 50(6): 1004-1005.
32. Iyalomhe GBS, Iyalomhe SI. Hypertension-related knowledge, attitudes and life-style practices among hypertensive patients in a sub-urban Nigerian community. *J Pub Health Epidemiol.* 2010; 2(4):71-77.
33. Amadi AN, Okafor GOC, Ikwudinma AO, Odu FU, Godswill-Ukoh EU. Adherence to lifestyle modifications among adult hypertensive Nigerians with essential hypertension in a primary care clinic of a tertiary hospital in a resource-poor environment of Eastern Nigeria. 2014; *Br J Med Med Res.* 4 (18): 3478-3490.
34. Akpa MR, Alasia DD, Emem-chioma PC. An appraisal of hospital based blood pressure control in Port Harcourt, Nigeria. *Nig Health J.* 2008; 27-30.
35. Van de Vijver S, Akinyi H, Oti S, Olajide A, Agyemang C, Aboderin I, Kyobutungi C. Status report on hypertension in Africa- Consultative review for the 6<sup>th</sup> session of the African Union Conference of Ministers of Health on non-communicable diseases. *Pan Afri Med J.* 2013; 16:38-DOI: 10.11604/panj.2013.16.38.3100.



36. Iyalomhe GBS, Omogbai EKI, Isah AO, Iyalomhe SI, Okhiai O, Dada FL, Iyalomhe OOB, Comparison of the long-term efficacy and some metabolic effects of initiating therapy with amlodipine or hydrochlorothiazide in hypertensive type 2 diabetic Nigerians. *Int J Health Sci Res.* 2014; 4 (7): 149-161.
37. Ogunleye OO, Ogundele SO, Akinyemi JO, Ogbera AO. Clustering of hypertension, diabetes mellitus and dyslipidemia in a Nigerian population: a cross sectional study. *Afr J Med Med Sci.* 2012; 41: 191-195.
38. Unadike BC, Eregie A, Ohwovoriole AE. Prevalence of hypertension amongst persons with diabetes mellitus in Benin City, Nigeria. *Nig J Clin Pract.* 2011; 14:300-302.
39. Stewart KJ, Bacher AC, Turner KL, Fleg JL, Hees PS, Shapero EP, Tayback M, Onyang P. Effects of exercise on blood pressure. *Arch. Int. Med.* 2005; 165: 756-762.
40. McBride P, Einerson J, Hanson P, Heindel K. Exercise and the primary prevention of coronary heart disease. *Med, Exerc, Nutr Health* 1992; 1: 5-15.
41. Haskell WL, Leon AS, Caspersen CJ. Cardiovascular benefits and assessment of physical activity and physical fitness in adults. *Med Sci Sports Exerc.* 1992; 24(6 Suppl):S201-20.
42. Blumenthal JA, Babyak MA, Hinderliter A. Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE study. *Arch Intern Med.* 2010; 170:126-135.
43. Whelton RK, Appel LJ, Espland MN for the Trial of Non-pharmacological Interventions in the Elderly (TONE) Collaborative Research Group. Sodium reduction and weight loss in the treatment of hypertension in older persons. *JAMA* 1998; 279: 839-846.
44. National Heart, Lung and Blood Institutes: Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults: The evidence report. *J Obesity Res.* 1998; 6 :515-2095.
45. Oladapo OO, Salako L, Sodiq O, Shoyinka K, Adebayo K, Falase AO. A prevalence of cardiometabolic risk factors among a rural Yoruba Southwestern Nigeria population: a population-based survey. *Cardiovasc J Afr.* 2010; 21(1): 26-31.
46. The Trials of Hypertension Prevention Collaborative Research Group: Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, Phase II. *Arch Intern Med.* 1997; 157:657-667.
47. Dahl LK. Salt and hypertension. *Am J Clin Nutr.* 1972; 25:231-235.
48. Oviasu VO, Okupa PE. Arterial blood pressure and hypertension in Benin in the equatorial forest zone of Nigeria. *Trop Geo Med.* 1980; 32:232-249.
49. Sever PS, Peart WS, Gordon D, Brighton P. Blood pressure and its correlates in urban and tribal Africans. *Lancet.* 1980; 2:60-63.
50. He FJ, Markandu ND, Sagnella GA, MacGregor GA. Modest salt reduction lowers blood pressure in both isolated systolic hypertension and combined hypertension. *Hypertens.* 2005; 46: 66-70.
51. Melander O, von Wöhrn F, Frandsen E, Burri P, Wilsteen G, Aurell M, Hulthén UL. Moderate salt restriction effectively lowers blood pressure and degree of salt sensitivity is related to baseline concentration of renin and N-terminal atrial natriuretic peptide in plasma. *J Hypertens.* 2007; 25(3):619-627.
52. Orbarzanek E, Proschan MA, Vollmer WM, Moore TJ. Individual blood pressure responses to changes in salt

- intake: results from the DASH-Sodium trial. *Hypertens.* 2003; 42:459-462.
53. Iyalomhe GBS, Omogbai EKI, Iyalomhe OOB, Iyalomhe SI. Serum and urine electrolyte profiles during amlodipine and hydrochlorothiazide combination therapy in Nigerian patients with essential hypertension. *Br J Med Med Res.* 2013; 3 (2): 428-441.
  54. Iyalomhe GBS, Omogbai EKI, Iyalomhe OOB. Long-term electrolyte effects during initiation of antihypertensive therapy with amlodipine or hydrochlorothiazide in diabetic Nigerians. *Am J Med Sci Med.* 2013; 1 (3): 1-7.
  55. Iyalomhe GBS, Omogbai EKI., Ozolua RI. Antihypertensive and biochemical effects of hydrochlorothiazide and furosemide in hypertensive Nigerians. *J Med Sci.* 7(6): 977-983.
  56. Iyalomhe GBS, Omogbai EKI, Ozolua RI, Dada FL, Iyalomhe OOB, 2008 Electrolyte profiles in Nigerian patients with essential hypertension. *Afr J Biotech.* 2007; 7(10): 1404-1408.
  57. Adroge HJ, Madias NE. Sodium and potassium in the pathogenesis of hypertension. *N Engl J Med.* 2007; 356:1966-1978.
  58. He FJ, MacGregor GA. How far should salt intake be reduced? *Hypertens.* 2003; 42: 1093-1099.
  59. Fuchs FO, Fuchs SC, Moreira LB, Gus M, Nobrega AC for PREVER-prevention trial. Prevention of hypertension in patients with prehypertension: protocol for the PREVER-prevention trail. *Trial.* 2011; 12:65.
  60. WHO, World Economic Forum. From burden to best buys: Reducing the economic impact of non-communicable diseases in low and middle-income countries. Geneva, 2001. <[http://www.who.int/nmh/publications/best\\_buys\\_summary.pdf](http://www.who.int/nmh/publications/best_buys_summary.pdf)> (Assessed 10/10/2014).
  61. He FJ, MacGergor GA. Reducing population salt intake worldwide: From evidence to implication, *Progress Cardiovasc Dis.* 2010; 16(8): 841-843.
  62. He FJ, Markandu ND, Colhart R, Barron J, MacGrogor GA. Effect of short-term supplementation of potassium chloride and potassium citrate on blood pressure in hypertension. *Hypertens.* 2005; 45: 571-574.
  63. Dickinson HO, Nicholson DJ, Campbell F, Beyer FR, Mason J. Potassium supplementation in the management of primary hypertension in adults. *Cochrane Data Base of System Rev.* 2006; 3: No CD 004641.DO1: 10:1002/14651858. CD 004691. pub2.
  64. Haddy FJ. Roles of salt, potassium, calcium, and natriuretic factors in hypertension. *Hypertens.* 1991; 18(suppl 111): S179-S183.
  65. Dwyer JK, Divyer KM, Scribner RA. Dietary calcium, calcium supplementation and blood pressure in African American adolescents. *Am J Clin Nutr.* 1998; 68: 648-655.
  66. Grobbee DE, Hofman A. Criteria for calcium supplementation in essential hypertension. *Lancet.* 1986; 2: 703-708.
  67. Geleijnse JM, Witterman JCM, Bak AAA, den Breijen JH, Grobbee DE. Reduction in blood pressure with a low sodium, high potassium, high magnesium salt in older subjects with mild to moderate hypertension. *BMJ.* 1994; 309: 436-440.
  68. Nijenhuis T, Vallon V, van der Kemp AW, Loffing J, Hoenderop JG, Bindels RJ. Enhanced passive Ca<sup>2+</sup> reabsorption and reduced Mg<sup>2+</sup> channel abundance explains thiazide-induced hypo-calciumuria and hypomagnesaemia. *J Clin Invest.* 2005; 115 (6): 1651-1658.
  69. Agraharkar M, Rondon – Berrios H, Fahlen M. Hypomagnesaemia. *eMed WebMed.* 2006; 1-11.
  70. Altura BM, Altura BT. Magnesium deficiency and hypertension: correlation between magnesium deficiency diet and microcirculatory changes in situ. *Science.* 1984; 223: 1325-1317.

71. Witterman JCM, Grobbee DE, Derk FHM, Bouillon AM, Hofman A. Reduction of blood pressure with oral magnesium supplementation in women with mild to moderate hypertension. *Am J Clin Nutr.* 1994; 60: 129 -135.
72. Harlan WR, Hull AL, Schmouder RL. Zinc levels in hypertensives. *Am J Epidemiol.* 1984; 120: 17-21.
73. He J, Whelton PK: Effect of dietary fiber and protein intake on blood pressure: A review of epidemiologic evidence. *Clin Exper Hypertens.* 1999; 21:785-796.
74. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM for the DASH Collaborative Research Group: A clinical trial of the effects of dietary patterns on blood pressure. *N Engl J Med.* 1997; 339: 1117-1124.
75. Lawoyin TO, Asuzu MC, Kaufman J, Rotimi C, Owoaje E, Johnson L, et al. Prevalence of cardiovascular risk factors in an African, urban inner city community. *West Afr J Med.* 2002; 21(3):208-11.
76. Witteman JC, Willett WC, Stampfer MJ, et al. Relation of moderate alcohol consumption and risk of systemic hypertension in women. *Am J Cardiol.* 1990; 65:633-637.
77. Klatsky AL, Guderson EP, Kipp H, Udaltsova N, Friedman GD. Higher prevalence of systemic hypertension among moderate alcohol drinkers: an exploration of the role of underreporting. *J Stud Alcohol.* 2006; 67:421-428.
78. Cushman WC, Cutler JA, Hanna E, Bingham SF, Follmann D, Harford T, for the Prevention and Treatment of Hypertension Study (PATHS): Effects of an alcohol treatment program on blood pressure. *Arch Int Med.* 1998; 158:1197-1207.
79. Ryu M, Kimm H, Jo J, Lee SJ, Jee SH. Association between alcohol intake and abdominal obesity among the Korean population. *Epidemiol Health.* 2010; 32:79-82.
80. American Heart Association (AHA) Science Advisory: Wine and your heart: a science advisory for healthcare professionals from the Nutrition Committee Council on Epidemiology and Prevention and Cardiovascular Nursing of AHA. *Circulation.* 2001; 103: 472-475.
81. Rimm EB, Williams P, Fosher K, Criqui M, Stampfer MJ. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. *BMJ.* 1999; 319:1523-1528.
82. Albert MA, Glynn RJ, Ridker PM. Alcohol consumption and plasma concentration of C - reactive protein. *Circulation.* 2003; 107:443-447.
83. Stockwell T, Greer A, Fillmore K, Chikritzhs T, Zeisser C. How good is the science? *BMJ.* 2012; 344:e2276.
84. Joshi P, Islam S, Pais P, et al. Risk for early myocardial infarction in South Asians compared with individuals in other countries. *JAMA.* 2007; 297:286-294.
85. Roy A, Prabhakaran D, Jeemon P, et al. Impact of alcohol on coronary heart disease in Indian men. *Atherosclerosis.* 2010; 210:531-535.
86. Marschner IC, Simes RJ, Keech A. Biases in the identification of risk factor thresholds and J-curves. *Am J Epidemiol.* 2007; 166:824-831.
87. Naimi T, Xuan Z, Saitz R. Immoderately confounding: the effects of low-dose alcohol. *Addiction.* 2013; 108:1552-1553.
88. Beaglehole R, Bonita R, Horton R, Adams C, et al. Priority actions for the non-communicable disease crisis. *The Lancet.* 2001; 377(9775):1438-47.
89. Primitesta, Falaschetti E, Gupta S, et al. Association between smoking and blood pressure: evidence from the health survey from England. *Hypertens.* 2001; 37:187-193.
90. Virds A, Giannarelli C, Neves MP, et al. Cigarette smoking and hypertension.

- Curr Pharm Design. 2010; 16:2518-2525.
91. Persoskie A, Kaulman AR, Leyva B. Receiving and adhering to lifestyle modification counseling for hypertension: Disparities between smokers and nonsmokers. *J. Clin Hypertens.* April 2014; DOI: 10.1111/jch.12314.
92. Rodgers A, Ezzati M, Vander Hoom S, Lopez AD, et al. Distribution of major health risk: findings from the Global Burden of Disease study. *PLoS Med.* Oct 2004; 1(1):e27.
93. Strawbridge WJ, Cohen R, Shema S, Kaplan G. Frequent attendance at religious services and mortality over 28 years. *Am J Public Health.* 1997; 87: 957-961.
94. Lawler-Row KA, Elliot J. The role of religious activity and spirituality in the health and wellbeing of older adults. *J Health Psychol.* 2009; 14:45-52.
95. Roll LL, Klemmack D, Parker M, Keong H, Sawyer-Barker P, Allman R. Religiosity, smoking, exercise, and obesity among Southern community dwelling older adults. *J Appl Gerontol.* 2005; 24:337-354.

How to cite this article: Iyalomhe GBS, Iyalomhe SI. The increasing burden of uncontrolled hypertension in Nigeria: the role of lifestyle modification practices as an effective strategy to reverse the trend. *Int J Health Sci Res.* 2015; 5(1):309-320.

\*\*\*\*\*

**International Journal of Health Sciences & Research (IJHSR)**

**Publish your work in this journal**

The International Journal of Health Sciences & Research is a multidisciplinary indexed open access double-blind peer-reviewed international journal that publishes original research articles from all areas of health sciences and allied branches. This monthly journal is characterised by rapid publication of reviews, original research and case reports across all the fields of health sciences. The details of journal are available on its official website ([www.ijhsr.org](http://www.ijhsr.org)).

Submit your manuscript by email: [editor.ijhsr@gmail.com](mailto:editor.ijhsr@gmail.com) OR [editor.ijhsr@yahoo.com](mailto:editor.ijhsr@yahoo.com)